Difference between revisions of "Ovarian cancer - historical"
Line 464: | Line 464: | ||
| style="background-color:#d73027" |Inferior OS | | style="background-color:#d73027" |Inferior OS | ||
|- | |- | ||
− | |[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19800515)45:10%3C2529::AID-CNCR2820451011%3E3.0.CO;2-4 Park et al. 1980] | + | |[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19800515)45:10%3C2529::AID-CNCR2820451011%3E3.0.CO;2-4 Park et al. 1980 (GOG 3)] |
|style="background-color:#1a9851"|Phase III (C) | |style="background-color:#1a9851"|Phase III (C) | ||
|1. 5-FU & Melphalan<br> 2. 5-FU, Dactinomycin, Melphalan<br> 3. 5-FU, Cyclophosphamide, Dactinomycin | |1. 5-FU & Melphalan<br> 2. 5-FU, Dactinomycin, Melphalan<br> 3. 5-FU, Cyclophosphamide, Dactinomycin | ||
+ | | style="background-color:#ffffbf" |Seems not superior | ||
+ | |- | ||
+ | |[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19830301)51:5%3C783::AID-CNCR2820510506%3E3.0.CO;2-Z Omura et al. 1983 (GOG 22)] | ||
+ | |style="background-color:#1a9851"|Phase III (C) | ||
+ | |1. Altretamine & Melphalan<br> 2. AC | ||
| style="background-color:#ffffbf" |Seems not superior | | style="background-color:#ffffbf" |Seems not superior | ||
|- | |- | ||
Line 476: | Line 481: | ||
# Young RC, Chabner BA, Hubbard SP, Fisher RI, Bender RA, Anderson T, Simon RM, Canellos GP, DeVita VT Jr. Advanced ovarian adenocarcinoma: prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med. 1978 Dec 7;299(23):1261-6. [https://www.nejm.org/doi/full/10.1056/NEJM197812072992301 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/101843 PubMed] | # Young RC, Chabner BA, Hubbard SP, Fisher RI, Bender RA, Anderson T, Simon RM, Canellos GP, DeVita VT Jr. Advanced ovarian adenocarcinoma: prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med. 1978 Dec 7;299(23):1261-6. [https://www.nejm.org/doi/full/10.1056/NEJM197812072992301 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/101843 PubMed] | ||
# '''GOG 3:''' Park RC, Blom J, Disaia PJ, Lagasse LD, Blessing JA. Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with the combination of cytoxan, 5-fluorouracil and dactinomycin. Cancer. 1980 May 15;45(10):2529-42. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19800515)45:10%3C2529::AID-CNCR2820451011%3E3.0.CO;2-4 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7378989 PubMed] | # '''GOG 3:''' Park RC, Blom J, Disaia PJ, Lagasse LD, Blessing JA. Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with the combination of cytoxan, 5-fluorouracil and dactinomycin. Cancer. 1980 May 15;45(10):2529-42. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19800515)45:10%3C2529::AID-CNCR2820451011%3E3.0.CO;2-4 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7378989 PubMed] | ||
+ | # '''GOG 22:''' Omura GA, Morrow CP, Blessing JA, Miller A, Buchsbaum HJ, Homesley HD, Leone L. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer. 1983 Mar 1;51(5):783-9. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19830301)51:5%3C783::AID-CNCR2820510506%3E3.0.CO;2-Z link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/6401594 PubMed] | ||
=Second-line therapy= | =Second-line therapy= |
Revision as of 03:57, 30 December 2018
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main ovarian cancer page for current regimens.
24 regimens on this page
39 variants on this page
|
Adjuvant chemotherapy for early stage disease
Cisplatin & Cyclophosphamide
back to top |
CP: Cyclophosphamide & Platinol (Cisplatin)
PC: Platinol (Cisplatin) & Cyclophosphamide
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Young et al. 2003 (GOG 95) | Phase III (C) | IP P32 | Seems not superior |
Preceding treatment
Chemotherapy
- Cisplatin (Platinol) 100 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
21-day cycle for 6 cycles
References
- GOG 95: Young RC, Brady MF, Nieberg RK, Long HJ, Mayer AR, Lentz SS, Hurteau J, Alberts DS. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study. J Clin Oncol. 2003 Dec 1;21(23):4350-5. link to original article contains protocol PubMed
First-line chemotherapy for advanced stage disease
Note: in a majority of these regimens, chemotherapy was preceded by primary debulking surgery.
CAP (Platinol)
back to top |
CAP: Cyclophosphamide, Adriamycin (Doxorubicin), Platinol (Cisplatin)
DCP: Doxorubicin, Cyclophosphamide, Platinol (Cisplatin)
PAC: Platinol (Cisplatin), Adriamycin (Doxorubicin), Cyclophosphamide
Regimen
Study | Evidence | Comparator | Efficacy | Toxicity |
---|---|---|---|---|
Conte et al. 1986 | Phase III (E) | CP | Seems not superior | |
Bolis et al. 1987 | Phase III (E) | 1. Cisplatin 2. CP |
Seems to have superior PFS | |
Alberts et al. 1989 (SWOG S7925) | Phase III (E) | 1. DC & BCG | Superior OS | |
2. DCP & BCG | Seems not superior | |||
Omura et al. 1989 | Phase III (E) | CP | Seems not superior | |
Parmar et al. 1998 (ICON2) | Phase III (C) | Carboplatin | Seems not superior | More toxic |
Parmar et al. 2002 (ICON3) | Phase III (C) | 1. Carboplatin 2. Carboplatin & Paclitaxel |
Seems not superior |
Chemotherapy
References
- Conte PF, Bruzzone M, Chiara S, Sertoli MR, Daga MG, Rubagotti A, Conio A, Ruvolo M, Rosso R, Santi L, Carnino F, Cottini M, Mossetti C, Guercio E, Gatti M, Siliquini PN, Prelato ML, Durando C, Giaccone G, Calciati A, Farinini D, Centonze M, Rugiati S, Parodi G, Messineo M, Storace A, Bernardini G, Misurale F, Alessandri S, Casini M, Ragni N, Foglia G, Bentivoglio G, Pescetto G. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. J Clin Oncol. 1986 Jun;4(6):965-71. Erratum in: J Clin Oncol 1986 Aug;4(8):1284. link to original article PubMed
- Bolis G, Marsoni S, Belloni C, Bianchi U, Bolis PF, Bortolozzi G, Colombo N, Epis A, Giardina G, Natale N, Pecorelli S, Redaelli U, Santoienna M, Valsecchi MG, Vassena L, Vergadoro F, Mangioni C; Gruppo Interegionale Cooperativo Oncologico Ginecologia. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet. 1987 Aug 15;2(8555):353-9. link to original article PubMed
- SWOG S7925: Alberts DS, Mason-Liddil N, O'Toole RV, Abbott TM, Kronmal R, Hilgers RD, Surwit EA, Eyre HJ, Baker LH. Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stages III and IV suboptimal disease ovarian cancer: a Southwest Oncology Group Study. Gynecol Oncol. 1989 Jan;32(1):8-15. link to original article PubMed
- Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1989 Apr;7(4):457-65. link to original article PubMed
- Meta-analysis: The Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol. 1991 Sep;9(9):1668-74. link to original article PubMed
- ICON2: Parmar MKB, Torri V, Bonaventura A, Bonazzi C, Colombo N, Delaloye JF, Marsoni S, Mangioni C, Sandercock J, Sessa C, and Williams C; ICON Collaborators. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer: International Collaborative Ovarian Neoplasm Study. Lancet. 1998 Nov 14;352(9140):1571-6. link to original article contains verified protocol PubMed
- ICON3: Parmar MKB, Adams M, Balestrino M, Bertelsen K, Bonazzi C, Calvert H, Colombo N, Delaloye JF, Durando A, Guthrie D, Hagen B, Harper P, Mangioni C, Perren T, Poole C, Qian W, Rustin G, Sandercock J, Tumolo S, Torri V, Vecchione F; International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002 Aug 17;360(9332):505-15. Erratum in: Lancet. 2003 Feb 22;361(9358):706. link to original article PubMed
CEP
back to top |
CEP: Cyclophosphamide, Epirubicin, Platinol (Cisplatin)
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Wils et al. 1999 | Phase III (C) | EP | Seems not superior |
Ray-Coquard et al. 2007 | Phase III (C) | Intensified CEP | Seems not superior |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Chemotherapy
References
- Wils J, van Geuns H, Stoot J, Bergmans M, Boschma F, Bron H, Degen J, Erdkamp F, van Erp J, Haest J, Iding R, Lalisang F, de Pree N, de Rooy C, Snijders M, Schepers J, Vreeswijk J, Wals J, Werter M, Wetzels L, Smeets J, Schouten L. Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic-IV ovarian cancer: a randomized phase III trial of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg. Anticancer Drugs. 1999 Mar;10(3):257-61. PubMed
- Ray-Coquard I, Paraiso D, Guastalla JP, Leduc B, Guichard F, Martin C, Chauvenet L, Haddad-Guichard Z, Lepillé D, Orfeuvre H, Gautier H, Castera D, Pujade-Lauraine E. Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group. Br J Cancer. 2007 Nov 5;97(9):1200-5. Epub 2007 Oct 9. link to original article link to PMC article PubMed
CHAD
back to top |
CHAD: Cyclophosphamide, Hexalen (Altretamine), Adriamycin (Doxorubicin), DDP (Cisplatin)
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Wadler et al. 1996 (ECOG E2878) | Phase III (E) | Melphalan | Seems to have superior TTTF |
Chemotherapy
References
- ECOG E2878: Wadler S, Yeap B, Vogl S, Carbone P. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. Cancer. 1996 Feb 15;77(4):733-42. link to original article PubMed
Cisplatin monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Fruscio et al. 2011 | Phase III (C) | Weekly cisplatin | Seems not superior |
Chemotherapy
- Cisplatin (Platinol) 75 mg/m2 IV once on day 1
21-day cycle for 6 cycles
References
- Mangioni C, Bolis G, Pecorelli S, Bragman K, Epis A, Favalli G, Gambino A, Landoni F, Presti M, Torri W, Vassena L, Zanaboni F, Marsoni S. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst. 1989 Oct 4;81(19):1464-71. link to original article PubMed
- Taylor AE, Wiltshaw E, Gore ME, Fryatt I, Fisher C. Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol. 1994 Oct;12(10):2066-70. link to original article contains protocol PubMed
- Fruscio R, Garbi A, Parma G, Lissoni AA, Garavaglia D, Bonazzi CM, Dell'anna T, Mangioni C, Milani R, Colombo N. Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer. J Natl Cancer Inst. 2011 Feb 16;103(4):347-51. Epub 2011 Jan 7. link to original article contains protocol PubMed
Cisplatin & Cyclophosphamide
back to top |
CP: Cyclophosphamide & Platinol (Cisplatin)
CPC: CisPlatin & Cyclophosphamide
PC: Platinol (Cisplatin) & Cyclophosphamide
Variant #1, 50/600
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Conte et al. 1986 | Phase III (C) | PAC | Seems not superior |
Chemotherapy
- Cisplatin (Platinol) 50 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 600 mg/m2 IV once on day 1
28-day cycle for 6 cycles
Variant #2, 50/750
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Kaye et al. 1992 | Phase III (E) | Cisplatin & Cyclophosphamide 100/750 | Inferior OS |
McGuire et al. 1996 (GOG 111) | Phase III (E) | Cisplatin & Cyclophosphamide 100/750 | Inferior OS |
Preceding treatment
- GOG 111: Primary debulking surgery, with suboptimal debulking
Chemotherapy
- Cisplatin (Platinol) 50 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
21-day cycle for 6 cycles
Variant #3, 50/1000
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Omura et al. 1989 | Phase III (C) | CAP | Seems not superior |
Chemotherapy
- Cisplatin (Platinol) 50 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 1000 mg/m2 IV once on day 1
21-day cycle for 8 cycles
Variant #4, 75/600
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Swenerton et al. 1992 | Phase III (C) | Carboplatin & Cyclophosphamide | Seems not superior |
Chemotherapy
- Cisplatin (Platinol) 75 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 600 mg/m2 IV once on day 1
28-day cycle for 6 cycles
Variant #5, 75/750
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
van der Burg et al. 1995 | Phase III (C) | Cisplatin & Cyclophosphamide, with interval debulking | Inferior OS |
McGuire et al. 1996 (GOG 111) | Phase III (C) | Cisplatin & Paclitaxel | Inferior OS |
Piccart et al. 2000 (OV10) | Phase III (C) | Cisplatin & Paclitaxel | Inferior OS |
Breitbach et al. 2002 | Phase III (C) | Cisplatin & Treosulfan | Seems not superior |
Note: the dosing for Breitbach et al. 2002 could not be confirmed from the abstract.
Preceding treatment
- GOG 111: Primary debulking surgery, with suboptimal debulking
- OV10: Primary debulking surgery, with optimal or suboptimal debulking
Chemotherapy
- Cisplatin (Platinol) 75 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
21-day cycle for 6 cycles
Variant #6, 100/600
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Alberts et al. 1992 | Phase III (C) | Carboplatin & Cyclophosphamide | Seems to have inferior OS |
Windbichler et al. 2000 | Phase III (C) | Cisplatin, Cyclophosphamide, IFN gamma | Seems to have inferior PFS |
Dittrich et al. 2003 | Phase III (C) | Carboplatin & Cisplatin | Seems not superior |
Chemotherapy
- Cisplatin (Platinol) 100 mg/m2 IV once on day 1 or 2
- Cyclophosphamide (Cytoxan) 600 mg/m2 IV once on day 1
21-day cycle for 6 cycles
Variant #7, 100/750
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Kaye et al. 1992 | Phase III (E) | Cisplatin & Cyclophosphamide 50/750 | Superior OS |
McGuire et al. 1996 (GOG 111) | Phase III (E) | Cisplatin & Cyclophosphamide 50/750 | Superior OS |
Chemotherapy
- Cisplatin (Platinol) 100 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
21-day cycle for 6 cycles
Variant #8, 100/1000
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Misset et al. 2001 | Phase II/III (C) | Cyclophosphamide & Oxaliplatin | Seems not superior |
Chemotherapy
- Cisplatin (Platinol) 100 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 1000 mg/m2 IV once on day 1
21-day cycle for 6 cycles
References
- Conte PF, Bruzzone M, Chiara S, Sertoli MR, Daga MG, Rubagotti A, Conio A, Ruvolo M, Rosso R, Santi L, Carnino F, Cottini M, Mossetti C, Guercio E, Gatti M, Siliquini PN, Prelato ML, Durando C, Giaccone G, Calciati A, Farinini D, Centonze M, Rugiati S, Parodi G, Messineo M, Storace A, Bernardini G, Misurale F, Alessandri S, Casini M, Ragni N, Foglia G, Bentivoglio G, Pescetto G. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. J Clin Oncol. 1986 Jun;4(6):965-71. Erratum in: J Clin Oncol 1986 Aug;4(8):1284. link to original article contains protocol PubMed
- Bolis G, Marsoni S, Belloni C, Bianchi U, Bolis PF, Bortolozzi G, Colombo N, Epis A, Giardina G, Natale N, Pecorelli S, Redaelli U, Santoienna M, Valsecchi MG, Vassena L, Vergadoro F, Mangioni C; Gruppo Interegionale Cooperativo Oncologico Ginecologia. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet. 1987 Aug 15;2(8555):353-9. link to original article PubMed
- Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1989 Apr;7(4):457-65. link to original article PubMed
- Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, Surwit EA, Malvlya VK, Nahhas WA, Jolles CJ. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 1992 May;10(5):706-17. Erratum in: J Clin Oncol 1992 Sep;10(9):1505. link to original article contains protocol PubMed
- Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stanimir R, O'Connell G, MacLean G, Kirk ME, Canetta R, Koski B, Shelley W, Zee B, Pater J. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1992 May;10(5):718-26. link to original article contains verified protocol PubMed
- Kaye SB, Lewis CR, Paul J, Soukop M, Rankin M, Cassidy J, Davis JA, Reed S, MacLean A, Kennedy JH, Symonds RP, Duncan ID, Gordon HK, Kitchener HC, Cruickshank DJ, Swapp GA, Sarkar TK, Atkinson RJ, Crawford SM. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet. 1992 Aug 8;340(8815):329-33. link to original article contains protocol PubMed
- van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Pecorelli S; Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med. 1995 Mar 9;332(10):629-34. link to original article PubMed
- GOG 111: McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996 Jan 4;334(1):1-6. link to original article contains verified protocol PubMed
- Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Müller-Holzner E, Marth C. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer. 2000 Mar;82(6):1138-44. link to original article link to PMC article contains protocol PubMed
- OV10: Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000 May 3;92(9):699-708. link to original article contains verified protocol PubMed
- Misset JL, Vennin P, Chollet PH, Pouillart P, Laplaige PH, Frobert JL, Castera D, Fabro M, Langlois D, Cortesi E, Lucas V, Gamelin E, Laadem A, Otero J. Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients. Ann Oncol. 2001 Oct;12(10):1411-5. link to original article contains protocol PubMed
- Breitbach GP, Meden H, Schmid H, Kühn W, Sass G, Schach S, Schmidt-Rohde P, Bastert G; GTOC Study Group. Treosulfan in the treatment of advanced ovarian cancer: a randomised co-operative multicentre phase III-study. Anticancer Res. 2002 Sep-Oct;22(5):2923-32. PubMed
- Dittrich Ch, Sevelda P, Salzer H, Obermair A, Speiser P, Breitenecker G, Schemper M, Kaider A; Austrian Ovarian Cancer Study Group. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin. Eur J Cancer. 2003 May;39(8):1129-40. Erratum in: Eur J Cancer. 2004 Mar;40(4):627. link to original article contains protocol PubMed
Hexa-CAF
back to top |
Hexa-CAF: Hexalen (Altretamine), Cyclophosphamide, Adrucil (Fluorouracil), Folex (Methotrexate)
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Young et al. 1978 | Phase III (E) | Melphalan | Superior OS |
Neijt et al. 1984 | Phase III (C) | CHAP-5 | Inferior OS |
Chemotherapy
References
- Young RC, Chabner BA, Hubbard SP, Fisher RI, Bender RA, Anderson T, Simon RM, Canellos GP, DeVita VT Jr. Advanced ovarian adenocarcinoma: prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med. 1978 Dec 7;299(23):1261-6. link to original article PubMed
- Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Vriesendorp R, Kooyman CD, van Lindert AC, Hamerlynck JV, van Lent M, van Houwelingen JC, Pindeo HM. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet. 1984 Sep 15;2(8403):594-600. link to original article PubMed
Melphalan monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Young et al. 1978 | Phase III (C) | Hexa-CAF | Inferior OS |
Park et al. 1980 (GOG 3) | Phase III (C) | 1. 5-FU & Melphalan 2. 5-FU, Dactinomycin, Melphalan 3. 5-FU, Cyclophosphamide, Dactinomycin |
Seems not superior |
Omura et al. 1983 (GOG 22) | Phase III (C) | 1. Altretamine & Melphalan 2. AC |
Seems not superior |
Chemotherapy
References
- Young RC, Chabner BA, Hubbard SP, Fisher RI, Bender RA, Anderson T, Simon RM, Canellos GP, DeVita VT Jr. Advanced ovarian adenocarcinoma: prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med. 1978 Dec 7;299(23):1261-6. link to original article PubMed
- GOG 3: Park RC, Blom J, Disaia PJ, Lagasse LD, Blessing JA. Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with the combination of cytoxan, 5-fluorouracil and dactinomycin. Cancer. 1980 May 15;45(10):2529-42. link to original article PubMed
- GOG 22: Omura GA, Morrow CP, Blessing JA, Miller A, Buchsbaum HJ, Homesley HD, Leone L. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer. 1983 Mar 1;51(5):783-9. link to original article PubMed
Second-line therapy
Tamoxifen monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Hurteau et al. 2010 (GOG 198) | Phase III (C) | Thalidomide | Seems not superior |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Hormonotherapy
Continued indefinitely
References
- GOG 198: Hurteau JA, Brady MF, Darcy KM, McGuire WP, Edmonds P, Pearl ML, Ivanov I, Tewari KS, Mannel RS, Zanotti K, Benbrook DM. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec;119(3):444-50. Epub 2010 Sep 17. link to original article PubMed
Intraperitoneal therapy
Cisplatin & Cyclophosphamide
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Alberts et al. 1996 (GOG 104) | Phase III (E) | Cisplatin (IV) & Cyclophosphamide | Seems to have superior OS |
Chemotherapy
References
- GOG 104: Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B, Adelson MD, Hoskins WJ. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996 Dec 26;335(26):1950-5. link to original article PubMed